Thyroid Cancer Awareness Month: CCIL Members Making Research Progress
Her research focuses on developing new therapeutic strategies for aggressive and treatment‑resistant thyroid cancers, particularly those for which current treatment options are limited.
The Cancer Center at Illinois highlights the research of Chitra Submaranian, focusing on new therapeutic strategies for aggressive and treatment‑resistant thyroid cancers. Her work aims to repurpose existing drugs, develop novel HSP90 inhibitors, and identify non‑invasive biomarkers to overcome resistance and improve clinical outcomes.
Progress in targeting HSP90 and repurposing drugs promises to overcome resistance to standard therapies in aggressive thyroid cancer, potentially improving survival and quality of life for patients with metastatic or radio‑iodine‑resistant disease.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management